These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268 [TBL] [Abstract][Full Text] [Related]
25. Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Holland EC; Hively WP; Gallo V; Varmus HE Genes Dev; 1998 Dec; 12(23):3644-9. PubMed ID: 9851971 [TBL] [Abstract][Full Text] [Related]
26. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289 [TBL] [Abstract][Full Text] [Related]
27. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
28. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. Põlajeva J; Sjösten AM; Lager N; Kastemar M; Waern I; Alafuzoff I; Smits A; Westermark B; Pejler G; Uhrbom L; Tchougounova E PLoS One; 2011; 6(9):e25222. PubMed ID: 21949886 [TBL] [Abstract][Full Text] [Related]
29. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Uhrbom L; Kastemar M; Johansson FK; Westermark B; Holland EC Cancer Res; 2005 Mar; 65(6):2065-9. PubMed ID: 15781613 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
31. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition. Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260 [TBL] [Abstract][Full Text] [Related]
32. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Li B; Chang CM; Yuan M; McKenna WG; Shu HK Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544 [TBL] [Abstract][Full Text] [Related]
33. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556 [TBL] [Abstract][Full Text] [Related]
34. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Tchougounova E; Kastemar M; Bråsäter D; Holland EC; Westermark B; Uhrbom L Oncogene; 2007 Sep; 26(43):6289-96. PubMed ID: 17438529 [TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Bachoo RM; Maher EA; Ligon KL; Sharpless NE; Chan SS; You MJ; Tang Y; DeFrances J; Stover E; Weissleder R; Rowitch DH; Louis DN; DePinho RA Cancer Cell; 2002 Apr; 1(3):269-77. PubMed ID: 12086863 [TBL] [Abstract][Full Text] [Related]
36. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035 [TBL] [Abstract][Full Text] [Related]
37. The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Dai C; Lyustikman Y; Shih A; Hu X; Fuller GN; Rosenblum M; Holland EC Neoplasia; 2005 Apr; 7(4):397-406. PubMed ID: 15967117 [TBL] [Abstract][Full Text] [Related]
38. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. Liu KW; Feng H; Bachoo R; Kazlauskas A; Smith EM; Symes K; Hamilton RL; Nagane M; Nishikawa R; Hu B; Cheng SY J Clin Invest; 2011 Mar; 121(3):905-17. PubMed ID: 21393858 [TBL] [Abstract][Full Text] [Related]
39. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Lindberg N; Kastemar M; Olofsson T; Smits A; Uhrbom L Oncogene; 2009 Jun; 28(23):2266-75. PubMed ID: 19421151 [TBL] [Abstract][Full Text] [Related]
40. Dietary energy balance modulation of Kras- and Ink4a/Arf+/--driven pancreatic cancer: the role of insulin-like growth factor-I. Lashinger LM; Harrison LM; Rasmussen AJ; Logsdon CD; Fischer SM; McArthur MJ; Hursting SD Cancer Prev Res (Phila); 2013 Oct; 6(10):1046-55. PubMed ID: 23980075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]